Brought to you by 
Juventas brings in $7.5mm through sale of B-2 equity, also secures $6mm in debt funding
04 Aug 2015
Executive Summary
Juventas Therapeutics Inc. (gene therapies for cardiovascular diseases) raised $7.5mm through a financing of B-2 preferred shares. Green Cross Holdings and Posco Capital led and were joined by new and returning investors. The company also sold $6mm in debt to Oxford Finance and could get another $9mm if specific milestones are met. The proceeds will support Phase IIb trials of JVS100 for chronic heart failure and late-stage peripheral artery disease.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Nonconvertible Debt
- Other
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Juventas brings in $7.5mm through sale of B-2 equity, also secures $6mm in debt funding
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice